Single User License
INR 168900
Site License
INR 337800
Corporate User License
INR 506700

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016

Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016


  Request for Sample Report

Executive Summary

Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 28

Prominent Drugs 30

Latest Clinical Trials News on Non-Small Cell Lung Cancer 31

Oct 13, 2016: OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 31

Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 31

Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 32

Oct 09, 2016: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer 33

Oct 09, 2016: Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck's KEYTRUDA (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients 34

Oct 09, 2016: Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer 36

Oct 09, 2016: Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study 37

Oct 09, 2016: Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016 38

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours 39

Oct 03, 2016: First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress 40

Oct 03, 2016: New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach 41

Sep 29, 2016: Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program 44

Sep 28, 2016: Two New Trials of Merck's KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 44

Sep 28, 2016: Merck to Present Phase II Program Updates on Tepotinib at ESMO 2016 45

Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress 46

Sep 26, 2016: Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 46

Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 47

Sep 25, 2016: New BGB324 study points to novel mechanism to enhance immunotherapy efficacy 48

Sep 23, 2016: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia in untreated adult ALK+ NSCLC patients 48

Sep 21, 2016: Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress 49

Sep 15, 2016: Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers 50

Sep 14, 2016: Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor 50

Sep 08, 2016: New analysis showed dose adjustment of Gilotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer 51

Aug 31, 2016: Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy 51

Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA 52

Aug 15, 2016: BeyondSpring Announces First Patient Enrolled in China in a Global Phase 3 Trial of Plinabulin for Non-Small Cell Lung Cancer 52

Aug 11, 2016: ValiSeek Clinical Development Update and Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia 53

Aug 10, 2016: Oncolytics Biotech Reports Additional Data from Randomized Phase II Study of REOLYSIN in Non-Small Cell Lung Cancer 53

Aug 09, 2016: Astrazeneca Update on Selumetinib Phase III Trial 54

Aug 09, 2016: Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo (nivolumab) in Treatment-Nave Patients with Advanced Non-Small Cell Lung Cancer 55

Aug 05, 2016: Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Nave Patients with Advanced Non-Small Cell Lung Cancer 55

Jul 25, 2016: Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 56

Clinical Trial Profile Snapshots 57

Appendix 3397

Abbreviations 3397

Definitions 3397

Research Methodology 3398

Secondary Research 3398

About GlobalData 3399

Contact Us 3399

Disclaimer 3399

Source 3400

List of Figures

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

GlobalData Methodology 3398

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29

Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca Plc, Pfizer Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, Novartis AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline Plc

Non-Small Cell Lung Cancer Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Non-Small Cell Lung Cancer, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com